IN2012DN01708A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01708A
IN2012DN01708A IN1708DEN2012A IN2012DN01708A IN 2012DN01708 A IN2012DN01708 A IN 2012DN01708A IN 1708DEN2012 A IN1708DEN2012 A IN 1708DEN2012A IN 2012DN01708 A IN2012DN01708 A IN 2012DN01708A
Authority
IN
India
Prior art keywords
tumors
folate
ovarian
methods
patient
Prior art date
Application number
Inventor
Christopher Paul Leamon
Richard Messmann
David Morgenstern
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of IN2012DN01708A publication Critical patent/IN2012DN01708A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FOLATE-TARGETED DIAGNOSTICS AND TREATMENT Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described are methods and compositions for treating folate receptor expressing epithelial tumors with a folate-vinca conjugate in combination with doxorubicin such as pegylated liposomal doxorubicin in which the tumors include ovarian  endometrial or non-small cell lung cancer tumors  including platinum-resistant ovarian tumors and platinum sensitive ovarian tumors. Also described are methods of treating platinum-resistant ovarian cancer using a folate-targeted drug  in the absence or presence of selecting the patient by identifying functionally active folate receptors on the tumors of the patient.
IN1708DEN2012 2009-07-31 2010-07-30 IN2012DN01708A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US34644410P 2010-05-19 2010-05-19
US35102210P 2010-06-03 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Publications (1)

Publication Number Publication Date
IN2012DN01708A true IN2012DN01708A (en) 2015-06-05

Family

ID=43529728

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1708DEN2012 IN2012DN01708A (en) 2009-07-31 2010-07-30

Country Status (13)

Country Link
US (2) US20120128587A1 (en)
EP (1) EP2460013A4 (en)
JP (1) JP2013501224A (en)
KR (1) KR20120050462A (en)
CN (2) CN104857534A (en)
AU (1) AU2010278734A1 (en)
BR (1) BR112012002064A2 (en)
CA (1) CA2769754A1 (en)
IL (1) IL217744A0 (en)
IN (1) IN2012DN01708A (en)
NZ (1) NZ598145A (en)
RU (1) RU2012105641A (en)
WO (1) WO2011014821A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187965B1 (en) 2007-08-17 2019-10-09 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
MX2013005194A (en) 2010-11-12 2013-06-28 Endocyte Inc Methods of treating cancer.
EP2696684A4 (en) * 2011-04-12 2014-11-05 Endocyte Inc Solid pharmaceutical composition
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
EP3057619A1 (en) 2013-10-16 2016-08-24 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
EA037778B1 (en) 2013-10-18 2021-05-20 Дойчес Кребсфоршунгсцентрум Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
ES2745799T3 (en) 2013-11-19 2020-03-03 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20170368208A1 (en) * 2015-01-11 2017-12-28 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope
EP3600430A4 (en) * 2016-03-29 2020-12-30 Endocyte, Inc. Folate conjugate for use in targeting tumor associated macrophages
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
EP3463367A4 (en) * 2016-05-25 2020-01-29 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI492750B (en) * 2003-01-27 2015-07-21 安德賽特公司 Vitamin-receptor binding drug delivery conjugates, pharmaceutical compositions, uses and preparation processes
KR101320936B1 (en) * 2004-12-21 2013-10-23 넥타르 테라퓨틱스 Stabilized polymeric thiol reagents
EP2452695A3 (en) * 2004-12-23 2013-01-23 Purdue Research Foundation Positron emission tomography imaging method
JP5289935B2 (en) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド Synthesis and purification of pteroic acid and its conjugates
AU2006230219A1 (en) * 2005-03-30 2006-10-05 Endocyte, Inc. Method for cancer prognosis using cellular folate vitamin receptor quantification
JP2006316040A (en) * 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
JP2010507659A (en) * 2006-10-25 2010-03-11 シェーリング コーポレイション How to treat ovarian cancer
ES2732879T3 (en) * 2007-06-25 2019-11-26 Endocyte Inc Conjugates containing hydrophilic spacer linkers

Also Published As

Publication number Publication date
IL217744A0 (en) 2012-03-29
AU2010278734A1 (en) 2012-02-23
WO2011014821A1 (en) 2011-02-03
US20140140925A1 (en) 2014-05-22
KR20120050462A (en) 2012-05-18
CA2769754A1 (en) 2011-02-03
EP2460013A1 (en) 2012-06-06
CN104857534A (en) 2015-08-26
RU2012105641A (en) 2013-09-10
NZ598145A (en) 2014-10-31
BR112012002064A2 (en) 2017-05-09
US20120128587A1 (en) 2012-05-24
CN102549434A (en) 2012-07-04
JP2013501224A (en) 2013-01-10
EP2460013A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
IN2012DN01708A (en)
Martin et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CY1118325T1 (en) ANALYSIS OF ANTI-CANCER UNITS THROUGH THE ACTIVITY OF NETRIN-1
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
WO2019094692A3 (en) Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
CY1118566T1 (en) DIAGNOSIS USING INTERFERENCE TYPE 1
MX347893B (en) Human antibody drug conjugates against tissue factor.
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
Roper et al. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
MX2014005800A (en) Human notch receptor mutations and their use.
Felip et al. Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer
PH12014502399A1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
EA201291260A1 (en) ANTIBODY AGAINST TROP-2 PERSON HAS ANTI-TUMOR ACTIVITY IN VIVO
CR10940A (en) VEGF SPECIFIC ANTAGONISTS FOR ADJUTIVE AND NEOADJUTIVE THERAPY AND TUMOR TREATMENT IN EARLY STAYS
MX2019000425A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer.
PL2223115T3 (en) Seprase as a marker for cancer
MX340724B (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer.
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
Perry et al. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
MX2013011431A (en) Methods for predicting and improving the survival of gastric cancer patients.
MY172580A (en) Tumor tissue based biomarkers for bevacizumab combination therapies
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target